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ORIGINAL ARTICLE
INTRODUCTION
Gastropathy refers to disorder in gastric mucosa
characterized by subepithelial bleeding and erosion. One
of the cause of gastropathy is NSAIDs (non steroidal
antiinflammatory drugs) aside from other factors such
as alcohol, stress or chemical agent. NSAIDs
gastropathy may cause varied clinical sign and
symptoms from dyspepsia, ulcer, erosion to perforation.
In Indonesia NSAIDs gastropathy is 2nd cause of
gastropathy after Helicobacter pylori and the 2nd cause
of upper gatrointestinal bleeding after esophagus
variceal rupture.1
Many kinds of NSAIDs start from the weakest to
the strongest potency to inhibit the prostaglandin
synthesis which is the potent mediator in inflammatory
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process may result in decreased sign of inflammation.
However, prostaglandin (PG) specially PGE2 has
protective effect for gastrointestinal mucosa mainly
the upper one. Inhibiton of PG at  one side will reduce
the inflamatory process in joints in soft tissues while in
the other side will reduce the defense mechanism of
gastric mucosa to other insult. This will make the acute
lesion on gastric mucosa and duodenum in the mild to
severe form.2 Rebamipide is a new drug which has the
potency to protect and resolve gastropathy. Rebamipide
has    specific mechanism of action as anti free radicals,
anti inflammation and also increase secretion of PG.3
This study is a triple blind clinical study.
Randomization had been used was block randomization
by determining the balanced block for every 4 subjects.
ABSTRACT
Background: Gastropathy represent a disparity of gastric mucosal characterized by sub-epithelial
bleeding and erosion. Gastropathy can be induced by non steroidal anti-inflammatory drugs (NSAIDs),
alcohol, stressor, and chemical agents with various sign and symptoms. NSAIDs-induced gastropathy is the
second most common etiology of gastric ulcer and variceal haemorrhages.
Aims: To investigate the effectivity of rebamipide compare with omeprazole in treatment of NSAIDs-
induced gastropathy.
 Method: This triple blind randomized study was enrolled from January to June 2004 with 38 subjects
who were recruited from outpatient and inpatient clinic in M Hoesin Hospital in Palembang. Subject was
divided into two groups. Endoscopic examination was performed in every patients.
Results: There was an improvement of symptom in rebamipide group (78.9%) and omeprazole group
(79.0%) after treatment but it didn’t have significant difference statistically. Improvement of NSAIDs
induced gastropathy after treatment between two groups have significant difference (P = 0.02), and
improvement of gradation of gastropathy after treatment has significant difference (P = 0.007).There was no
side effect of administration of rebamipide and omeprazole in each group.
Conclusion: Rebamipide as effective as omeprazole in improvement of symptom. Omeprazole is more
effective than rebamipide in improvement of NSAIDs induced gastropathy and is as safe as rebamipide in the
treatment of NSAIDs induced gastropathy.
Keywords: Gastropathy, NSAIDs, rebamipide, omeprazole.
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This study was conducted in our hospital, rheumatology
clinic, Internal Medicine ward from January to June 2004.
Sample size involved 38 patients who were
divided into 2 groups.
Inclusion criterias were patients whose age
15-65 years old, receiving NSAIDs, had the symptoms
of dyspepsia, endoscopic finding in accordance with
NSAIDs gastropathy, agreed to participate in the study
and sign the informed consent form. The exclusion
criteria were reflux esophagitis, pyloric stenosis,
pregnancy, on steroid treatment, had chronic disease such
as heart disease, hypertension, diabetes, kidney disease,
liver disease and malignancy. Rejection criteria were
the patients stop using the drugs or died by any cause of
death, had complication or severe side effects of trial
drug which made the drug had to be stopped and
pregnancy during the study period.
Effectiveness Parameter
The effectiveness of therapy was evaluated by
endoscopy; decreased grade of lesion and milder
clinical symptoms of dyspepsia. To evaluate mucosal
disturbance we used Modified Lanza Score (MLS)
criteria:4
The grading systems according to MLS is as follows:
• Grade 0 : no erosion or bleeding
• Grade 1 : erosion and bleeding in one area or
  number of lesion ≤ 2
• Grade 2 : erosion and bleeding in one area or
  there are 3-5 lesions
• Grade 3 : erosion and bleeding in two areas or
  thereare 6-10 lesions
• Grade 4 : erosion and bleeding > 3 areas or more
  in gaster
• Grade 5 : there is already gastric ulcer
The grade 4 an 5 were included in this study.
Clinical symptoms of dyspepsia are characterized by
epigastric pain, heartburn, nausea, vomit, fullness, and
anorexia. Dyspepsia is divided into:5
• Mild dyspepsia : if the symptoms are well tolerated
by patients
• Moderate dyspepsia : if the symptoms are already
disturbing but patient can still do normal daily
activities
• Severe dyspepsia : if patients cannot do normal daily
activities
The improvement conditions by endoscopic findings
are divided into 5 categories :
• Mild improvement : decreased one grade level
• Moderate improvement : decreased two grade
levels
• Good improvement : decreased grade of dyspepsia
> 3 levels
• No improvement : no decreased grade of dyspepsia
• Worsening : increased grade of dyspepsia
MATERIAL AND METHODS
Each patients with NSAIDs gastropathy included in
this study had been made individual form containing
patient’s identity, anamnesis, physical examination,
endoscopic examination, laboratory examination.
The patients were divided into 2 groups A and B. Group
A were given rebamipide 100 mg three times daily and
sodium diclofenac 50 mg three times daily for 2 weeks.
Group B were given omeprazole 20 mg once daily and
natrium diclofenac 50 mg three times daily for two
weeks.
 During study, observation was done on clinical
response and symptoms related to the use of trial drugs.
In the end of 2nd week laboratory and endoscopic
examination was repeated. The data was collected on
research forms. Data was analysed by chi-square test
and continuous data analyzed by student t-test with
significance level of P < 0.05.
RESULT
Subject Characteristics
Various ethinic races in South Sumatera from
Palembang, OKU, OKI and Sekayu and those from other
regions including Padangnese, Bataknese and Javanese.
Higher level educations included  high school and
college. Complete data is shown in table 1.
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T a ble  1 . S tud y Sub jec t C ha ract erist ic s (N  = 38 ) 
C hara c ter istic  R e ba m ip id e  G ro up 
n  (% )  
O m ep ra zole  G r o up  
n  ( % ) P  
G en d er     
 M a le  
F e m ale  
6 (3 1. 6) 
1 3  (6 8 .4)  
5  (2 6 .3)  
14  ( 73 .7 ) 
0 .7 2*  
M ean  o f A g e  (x  ±  SD ) 5 5. 79  ±  6. 13  5 6 .2 1 ±  7 .1 3 0. 84 **  
A g e  G ro up    0 .5 0*  
 4 0 -4 9 
5 0 -5 9 
> 5 9 
3 (1 5. 8) 
1 0  (5 2 .6)  
6 (3 1. 6) 
4  (2 1 .1)  
7  (3 6 .8)  
8  (4 2 .1)  
 
E d uca t io n   1 .0 0*  
 H igh  sch oo l  
C o lle g e  
8 (4 2. 1) 
1 1  (5 7 .9)  
8  (4 2 .1)  
11  ( 57 .9 ) 
 
E m p lo y m ent  s ta tus   0 .7 5*  
 E m plo ye d  
U n em plo ye d  
1 0  (5 2 .6)  
9 (4 7. 4) 
9  (4 7 .4)  
10  ( 52 .6 ) 
 
E thn ic   0 .6 4*  
 S ou th Su m ater a 
O u ts id e  So uth Su m a ter a  
1 7  (8 9 .5)  
2 (1 0. 5) 
16  ( 84 .2 ) 
3  (1 5 .8)  
 
N ote :  *  C hi-s qu are , **  t -te st 
Table 2. Treatment Effect on Laboratory Examination 
Characteristic 
Rebamipide Group Omeprazole Group p 
After 
X ± SD 
Before 
X ± SD p** 
After 
X ± SD 
Before 
X ± SD p**  
Hemoglobin 12.77 ± 1.39 12.71 ± 1.33 0.76 12.97 ± 1.28 12.82 ± 0.87 0.34 0.23 
WBC 8,652.63 ± 2,318.37 7,484.21 ± 1677 0.08 8,936.84 ± 2,623.02 7,321.05 ± 1,848.59 0.25 0.77 
LED 27.47 ± 20.59 27.63 ± 18.57 0.97 36.47 ± 26.69 26.74 ± 17.17 0.06 0.87 
Basophyl 0 0  0 0   
Eosinophyl 2.21 ± 1.87 1.58 ± 1.50 0.30 2.16 ± 2.45 2.53 ± 2.69 0.62 0.18 
Netrophyl bar 1.32 ± 0.94 3.63 ± 4.41 0.04 1.53 ± 1.26 1.74 ± 1.36 0.64 0.08 
Netrophyl 
segment 64.42 ± 8.42 62.05 ± 6.61 0.28 66.00 ± 7.83 65.63 ± 5.79 0.84 0.08 
Thrombosis 267,157.89 ± 60,676.98 282,368.42 ± 57368.41 0.14 301,473.68 ± 97,917.40 276,842.11 ± 62,338.91 0.10 0.77 
BSS 88.00 ± 26.28 86.26 ± 19.07 0.74 92.32 ± 30.77 84.79 ± 14.89 0.16 0.79 
BUN 26.37 ± 13.58 21.58 ± 7.71 0.08 31.16 ± 21.60 22.89 ±11.07 0.16 0.67 
Creatinine 1.11 ± 0.27 0.98 ± 0.20 0.03 1.05 ± 0.46 0.96 ± 0.31 0.20 0.81 
ALT 37.58 ± 10.29 34.47 ± 12.58 0.19 43.16 ± 10.83 37.63 ± 10.91 0.01 0.41 
AST 34.00 ± 13.54 27.79 ± 12.61 0.04 38.89 ± 14.13 34.00 ± 14.62 0.09 0.17 
Alkaline 
phosphatase 111.79 ± 48.31 119.26 ± 59.89 0.33 114.47 ± 54.71 104.42 ± 47.24 0.36 0.40 
Note: x = mean, SD = standard deviation 
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Figure 1. Treatment Effects on Clinical Symptoms of Dyspepsia
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F igure 2 . C linical Improvement after T reatment 
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Table 3. Improvement of NSAIDs Gastropathy after Treatment 
Treatment of NSAIDs 
Gastropathy 
Rebam ipide Group  
n (%) 
Omeprazole Group 
n (%) 
p 
Mild 4 (21.1) 2 (10.5) 0.02 
Moderate 5 (26.3) 3 (15.8)  
Good 3 (15.8) 13 (68.4)  
No Improvement 3 (15.8) -  
Worsening 4 (21.1) 1 (5.3)  
Total 19 (100) 19 (100)  
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DISCUSSION 
Treatment  effects  on  clinical  symptoms 
of dyspepsia 
The result of this study showed lower clinical response  
compare to those study conducted by Keiji et al.,  
Hawkey et al., and Yeomans et al.5-7 This might be due  
to shorter period of time (only 2 weeks), while other  
study observed for trreatment in 4-8 weeks. The sample  
size in this study was also smaller compare to the other  
ones. 
Improvements of NSAIDs gastropathy after 
Treatment 
Clinical improvements of NSAIDs gastropathy would  
be better if the patients stop using NSAIDs. To maintain  
high cure rate, anti secretory agents to neutralize the  
gastric acid is needed, so the restitution process could 
go well.1,3,8 
The combination of rebamipide and PPI was  
superior to PPI alone (P < 0.05) was reported by  
Tsukamoto et al. Miwa T also reported ulcer healing by  
rebamipide and ranitidine was 90% compare to ranitidine  
alone which only reached 77 % (P < 0.05).9 The high  
response rate was   also reported by Higuchi et al.,  
the cure rate was 100% for group of omeprazole +  
rebamipide and omeprazole + amoxicillin, 96% for  
omeprazole alone.10 
Other researchs were conducted to study  
the protective effect of rebamipide like one had been 
reported by Naito et al.4 He observed protective effect 
of rebamipide to indomethacin compare to placebo. 
Clinical symptoms of dyspepsia were found in 43% 
patients and 80% in the placebo group. In the therapy 
group, grade 1 gastropathy NSAIDs was found in 86%, 
grade 2 was 14%. In the placebo group NSAIDs 
gastropathy grade 1 was found in 30%, grade 2-4 was 
40% and grade 5 was 30% (P < 0.05). 
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Damman11 reported rebamipide had decreased 
number of lesions in the antrum as much as 96% in 
therapy group and 77.3% in placebo group (P = 0.015). If   
the observation of lesion was done thoroughly 
including corpus, antrum and duodenum bulbus, 
rebamipide had decreased number of lesions to 141.5% 
and 115.2% in placebo group (P = 0.058). 
The treatment effects of rebamipide in this study was  
not superior compare to other study because it was  
conducted   in shorter period of time (2 weeks) and  
the sample size were also smaller than those in other  
studies. Aside from that, the high cure rate might be due  
anti secretory used. Protective effect of rebamipide was  
more prominent than cure rate on gastric mucosal lesion  
due to NSAIDs. In the omeprazole group decreased  
degree of NSAIDs gastropathy before and after  
treatment was significant (P = 0.00). This result was not  
different from study conducted by other researchers:  
Yeomans et al., Djojoningrat, Langman et al., Hawkey  
et al., and Agrawal et al.5,7,12,13,14 In group of omeprazole  
the worsening of NSAIDs gastropathy was also observed  
in 5.3%. This was caused by individual difference of  
gastric acid level for each patient.8,13 In high level of  
gastric acid, the antisecretory treatment like PPI was  
very beneficial for the patients in ulcer healing  
process.8,15,16 In neutral or low level gastric acid level,  
the antisecretory treatment would not be very  
beneficial. In this case, cytoprotective drugs such as  
rebamipide, prostaglandin analog, cetraxate could be used  
to increase defensive factors for optimizing healing 
process.8,15,16 
Comparison of Adverse Effect 
In all patients who were given rebamipide, we  
observed no adverse effect like hypersensitivity, rash,  
pruritus, drug eruption, constipation, diarrhea, vomit,  
menstrual disturbance or edema. The same was also  
observed in omeprazole group, like reported by other 
studies.17-19 
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Table 4. Decreased Severity of NSAIDs Gastropathy after Treatment (N = 38) 
NSAIDs 
Gastropathy 
Rebamipide Group Omeprazole Group 
p After 
X ± SD 
Before 
X ± SD p 
After 
X ± SD 
Before 
X ± SD p 
Degree 0 0 0 0.004 0 6 (31.6) 0.000 0.007 
Degree 1 0 1 (5.3)  0 5 (26.3)   
Degree 2 0 4 (21.1)  0 5 (26.3)   
Degree 3 0 6 (31.6)  0 1 (5.3)   
Degree 4 12 (63.2) 5 (26.3)  12 (63.2) 1 (5.3)   
Degree 5 7 (36.8) 3 (15.8)  7 (36.8) 1 (5.3)   
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CONCLUSION
Rebamipide and omeprazole were both effective in
decreasing clinical symptoms of dyspepsia. The
differences in decreased symptoms was not different
significantly between both groups (P = 0.09). Omeprazole
was more effective in gastropathy NSAIDs than
rebamipide (P < 0.05). Rebamipide and omeprazole were
considered safe because no adverse event occurred
during the study.
SUGGESTION
Further studies on protective effects iof rebamipide
on gastric mucosal lesion due to NSAIDs gastropathy
are required. Omeprazole may be used for NSAIDs
gastropathy treatment.
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